| July 28 - August 4, 2014|
Treatment Target 2020...
"The retargeting discussions should not be limited by financial and funding possibilities: we should start from real demands from the ground. The question is not how can we do it. The question is—how can we not?"
- Aaron Motsoaledi, Minister of Health, South Africa. Speaking at IAS
... to Ben Youngblood on receiving his first ever NIH funding (1R56AI114442-01)
It is no mystery that HIV-specific T-cell responses decline during the long years of chronic HIV infection. What IS a mystery is why they do so even with HAART on board. Ben Youngblood's R56 -- Epigentic Regulation of T-Cell Exhaustion During Treated Chronic HIV Infection -- is designed to delve into the mechanism(s) that mediate that progressive decline.
In other news...
Read the project Abstract
... to Michael Roe (July 29), and
Rob Stephenson (August 2)
We are REALLY glad you were born.
... Is sugar bad or good for you? Maybe both. For example, a virion of HIV that has a lot of glycans (sugar-coated proteins) on its outer envelope may be protected from attack by HIV-specific antibodies. But that same thick coating of glycans may also make the virion less fit, from a transmission standpoint, than HIV that is lightly glycosylated. Sid Byrareddy's new award (his first R01!) -- Role of HIV Env Glycosylation in Mucosal Transmission (1R01AI113883-01) -- is designed to systematically identify the role of glycans in viral transmission.
• Read the project Abstract
Cure scientists are working on ways to completely eradicate HIV from reservoirs. But how will we know when we reached the goal line? Francois Villinger and Philip Santangelo's new R01 -- Monitoring SIV Reservoirs with Whole Body Immunopet (1R01AI111907-01) is working on that. Specifically, they will use optimized imaging to create real-time, whole body maps of SIV infection in RMs in order to identify viral reservoirs and the sites from which SIV reemerges after interruption of treatment.
• Read the project Abstract
Fair dinkum erratum to last week's Spotlight. Andres Camacho-Gonzalez and Ralph DiClemente were also on site in Melbourne.
HIV Prevention Counseling Trainees Sought:
Prevention Science Core
• WHAT: Training in the fundamentals of HIV Prevention Counseling(FHPC)
• WHEN: August 25-27, 2014; 9am to 3pm
• WHERE: RSPH
• FEE: $100/person; paid by check
(some subsidies are available)
• OUTCOME: There will be opportunities for those who complete the course to put their skills to work through several studies at RSPH and local CBOs.
NEXT TRAINING: January, 2015
• QUESTIONS: Email Marcus Stanley
Eugene McCray to serve as the Director of the CDC's Division of HIV/AIDS Prevention (DHAP) in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
Jono Mermin announced that beginning August 11, 2014, Eugene McCray will serve as the Director of DHAP, replacing Ken Castro who has been serving as DHAP Acting Director for the last year. Eugene is a globally recognized expert in HIV and TB and helped start and then lead the CDC's Global AIDS Program.
• Read Jono Mermin's announcement
• Read Eugene McCray's CDC biography
STANDARD AIDS DATES
Arts-Based Approaches in Palliative Care for Symptom Management
October 13 (LOI)
Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth
October 21 (LOI)
Mucosal Environment and HIV Prevention (MEHP II)
See previously advertised Funding Opportunities in Network News archived issues.
Call for Papers
Public Health Reports
Supplemental Issue on Implementation of
Routine HIV Screening in Clinical Settings
Deadline: September 15, 2014
that acknowledge the CFAR grant
Haley DF, Golin C, El-Sadr W, Hughes JP, Wang J, Roman Isler M, Mannheimer S, Kuo I, Lucas J, DiNenno E, Justman J, Frew PM, Emel L, Rompalo A, Polk S, Adimora AA, Rodriquez L, Soto-Torres L, Hodder S.
Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study.
J Womens Health (Larchmt). 2014 Jun;23(6):541-51.
Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier MJ, Ende ZS, Klatt NR, DeZiel CE, Lin TH, Peng J, Seese AM, Shapiro R, Frater J, Ndung'u T, Tang J, Goepfert P, Gilmour J, Price MA, Kilembe W, Heckerman D, Goulder PJ, Allen TM, Allen S, Hunter E.
HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.
Science. 2014 Jul 11;345(6193):1254031.
Lippman SA, Périssé AR, Veloso VG, Sullivan PS, Buchbinder S, Sineath RC, Grinsztejn B.
Acceptability of self-conducted home-based HIV testing among men who have sex with men in Brazil: data from an on-line survey.
Cad Saude Publica. 2014 Apr;30(4):724-34.
Mangal JP, Rimland D, Marconi VC.
The continuum of HIV care in a Veterans' Affairs clinic.
AIDS Res Hum Retroviruses. 2014 May;30(5):409-15.
- July 30 & August 2
- Grant Writing Tutorial
NIH K and Other Career Development Awards
Target Audience: Postdocs, Instructors, Asst. Profs
Sponsor: Office of Postdoctoral Education
- July 31 - ABSTRACT DEADLINE
HIV & Aging: From Mitochondria to the Metropolis
Location: Marriott Courtyard, Decatur
• Call for Abstracts
Farther Down the Road
- August 8 (Abstracts deadline)
December 8-9 (Meeting)
7th Annual Conference on the Science of Dissemination and Implementation:
Transforming Health Systems to Optimize Individual and Population Health
- August 15 (Abstracts deadline)
November 11-14 (Meeting)
32nd Annual Symposium on Nonhuman Primate Models for AIDS
Host: Oregon National Primate Research Center
Location: Portland, OR
- September 9 (Abstracts open)
October 1 (Abstract deadline)
December 2 (Late Breaker opens)
January 8 (Late Breaker deadline)
February 23-26 (Meeting)
- October 3-5
American Mock World Health Organization (AMWHO)
Target Audience: Graduate Students
Location: UNC Chapel Hill
- October 23-24
- 8th Annual SBSRN National Meeting
Disparities in Research, Clinical Treatment, Prevention and Policies: A Call to Action
Host: UCLA CFAR
Location: Los Angeles
• Information and Registration
Spotlight! | Godzilla (HIV) vs Mothra (Ebola)
We've come a long way, baby.
As if news about the resurgence in measles and polio isn't enough, the escalating and still uncontained outbreak of Ebola Virus Disease (EVD), formerly known as Ebola Hemorrhagic Fever, in Sierra Leone, Liberia, and Guinea is making it clear that the jury is no longer out on Arthur Reingold's year 2000 rhetorical question: "Infectious Disease Epidemiology in the 21st Century: Will It Be Eradicated or Will It Reemerge?" (Epidemiologic Reviews).
This West African outbreak of Ebola is already the worst in recorded history with 1,201 cases and 672 deaths attributed through 7/23/14, including 108 new cases in the most recent 3 day reporting period alone.
Furthermore, in the era of rapid international travel, it is highly likely that Ebola cases can and will spread and, in fact, this past weekend Nigeria reported its first case, after an air traveller from Liberia became fatally ill during an international flight that landed in the Nigerian capital city of Lagos, after a stop over in Togo.
About Ebola... Like HIV, there is no vaccine or curative therapy for Ebola, nor is there likely to be one soon. Unlike HIV however, Ebola has a very rapid incubation period (2-21 days), which makes the use of quarantining infected people a logical tool in containing the outbreak. Furthermore, unlike HIV, Ebola is highly contageous and health care providers are at high risk of infection -- the top Ebola doctor in Sierra Leone is ill, the senior doctor at Liberia's largest hospital has just died, and two US medical staffers are currently in isolation.
if there is any glimmmer of light in the unfolding tragedy it is that the current mortality rate (~56%) is substantially less than is typical (90%) for EVD.
All of this throws into stark relief just how far we have come since the days in which HIV/AIDS was itself a death sentence making a seemingly unstoppable march across the globe.
According to the Global Fund to Fight AIDS, Tuberculosis, and Malaria, "HIV and AIDS are in retreat." Their website claims that 6.6 million people around the world are currently receiving ARV therapy, extending life spans and curbing transmission.
This, in conjunction with CFAR-led advances in vaccine science and social and behavioral interventions, has and will continue to make huge strides towards our collective goal of ending the global suffering from HIV/AIDS.
So as our CFARian friends and colleagues come home from Melbourne full of news about advances discussed at the conference, let us all take a moment to be mindful of the unfolding Ebola tragedy and the reminder it provides about just how far all of us -- HIV/AIDS researchers, activists, and PLWAs -- have come.
The Network News is a periodic email, detailing HIV/AIDS related events, funding opportunities, and achievements of CFAR members. If you have items that you wish to have included, please send them to us at email@example.com by Friday of each week. Please put "The Network News" in the subject line.
The Network News is distributed to CFAR members by email every Monday. Except when it isn't.
Editor, Kimberley Sessions Hagen, EdD